skip to Main Content

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.

According to investigators, these findings could help guide treatment decisions and future studies as well as suggest new biomarkers for exploration. Read more . . . 


Back To Top